Table 1. Study characteristics.
| Study | Recruitment years | Location of institution | Study design | Patient population | Number of patients (n) | Follow up (median) [range] | Patient age (years) [range] |
|---|---|---|---|---|---|---|---|
| Reul 1989 | 1979–1984 | Houston, Texas (USA) | Single-centre retrospective | NVE and PVE | Total =185 | BV =22 months [6–68 months] | BV =49 [8–77] |
| BV =88 | MV =18 months [6–70 months] | MV =46.6 [11–78] | |||||
| MV =97 | |||||||
| Lytle 1996 | 1975–1992 | Cleveland, Ohio (USA) | Single-centre retrospective (registry data) | PVE | Total =128 | – | – |
| BV =52 | |||||||
| Mv =76 | |||||||
| Moon 2001 | 1964–1995 | Stanford, California (USA) | Single-centre retrospective | Left-sided valve IE (NVE and PVE) | Total =286 | Overall =15.3 years [0–29 years] | Overall =49 |
| BV =221 | |||||||
| MV =65 | |||||||
| Fedoruk 2009 | 1975–2000 | British Columbia, Vancouver (Canada) | Multi-centre retrospective (registry data) | NVE | Total =358 | Overall =5.5±5.5 years | Overall =48.8±15.9 [18–88] |
| BV =189 | BV =6.1±6.1 years | BV =51.6±17.3 | |||||
| MV =169 | MV =4.9±4.5 years | MV =45.6±13.5 | |||||
| Musci 2010 | 1986–2008 | Berlin (Germany) | Single-centre retrospective | PVE | Total =210 | – | – |
| BV =165 | |||||||
| Mv =45 | |||||||
| Nguyen 2010 | 1998–2000 | France | Multicentre prospective | Aortic valve IE (NVE and PVE) | Total =140 | – | Overall =57.9±13.0 |
| BV =31 | BV =63.2±13.6 | ||||||
| MV =109 | MV =57.3±11.6 | ||||||
| Jassar 2012 | 2000–2010 | Philadelphia, Pennsylvania (USA) | Single-centre retrospective | ARR for IE | Total =98 | BV =31.7±28.5 months | BV =62.7±15.1 |
| BV =43 | MV =27.4±22.1 months | MV =51.8±12.7 | |||||
| MV =55 | |||||||
| Leither 2013 | 2004–2007 | USA | Multi-centre retrospective (registry data) | Renal-replacement therapy patients with NVE affecting aortic or mitral valve | Total =1267 | – | – |
| BV =561 | |||||||
| MV =706 | |||||||
| Greason 2014 | 1974–2009 | Rochester, Minnesota (USA) | Single-centre retrospective (registry data) | PVE affecting the MV | Total =36 | Overall =5.7 years [0.6–24 years] | Overall =68 [15.8–82.3] |
| BV =18 | |||||||
| MV =18 | |||||||
| Delahaye 2015 | 2000–2006 | Global | Multicentre prospective | Patients with IE undergoing valve surgery in the acute phase | Total =1,467 | – | Overall =56.6±15.7 |
| MV =917 | BV =61.6±15.2 | ||||||
| MV =917 | MV =53.6±15.2 | ||||||
| Kim 2016 | 2002–2014 | Boston, Massachusetts (USA) | Multicentre prospective | Adult patients with AVE | Total =218 | Overall =29.4 months [4.7–72.6 months] | BV =59.8±14.6 |
| BV =139 | MV =47.2±14.5 | ||||||
| MV =79 |
NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; IE, infective endocarditis; BV, bioprosthetic valve; MV, mechanical valve.